Company Overview and News
On July 10, Bursa Securities had issued a show-cause notice to China Automobile Parts Holdings Ltd on the commencement of trading suspension,
KUALA LUMPUR (March 1): The FBM KLCI hovered just below the 1,700 level at the midday break, as buyers and sellers were almost eqully balanced.
KUALA LUMPUR (Jan 9): The 1,700 psychologically crucial threshold remained elusive for the FBM KLCI at the midday break today as sellers outpaced buyers.
KUALA LUMPUR (Jan 9): The FBM KLCI struggled this morning to breach the crucial 1,700-points level and remained in the negative zone at mid-morning.
KUALA LUMPUR (Oct 25): The FBM KLCI dipped at mid-morning today, weighed by losses at select blue chips.
KUALA LUMPUR (July 25): The FBM KLCI pared some of its gains at the midday break today, as sentiment is seen volatile over the continuing 1Malaysia Development Bhd saga, with the developments last week in the U.S.
KUALA LUMPUR (July 15): Based on corporate announcements and news flow today, companies that may be in focus on Monday (July 18) could include: Ambank Group, SKP Resources, China Automobile, Magna Prima and Axiata.
KUALA LUMPUR (June 15): The FBM KLCI reversed its earlier losses at the midday break today, lifted by select blue chips, but the broader market sentiment remained wary in line with the weaker regional markets.
KUALA LUMPUR (June 14): The FBM KLCI pared some of its losses at the midday break today but sentiment remained jittery in line with weaker regional markets.
KUALA LUMPUR (June 7): The FBM KLCI tracked regional gains to close at a high of 1,660.62 points today, supported by diminishing expectations of a near-term US interest rate hike.
KUALA LUMPUR (June 3): The FBM KLCI notched up limited gains at the midday break today, as decliners outpaced gainers.
KUALA LUMPUR (May 26): The FBM KLCI pared some of its gains at the midday break today as sellers outpaced buyers at tghe local market.
KUALA LUMPUR (March 1): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Wednesday, March 2) could include the following: Econpile, PPB, CIMB, HeveaBoard, Sime Darby, Fajarbaru, Kuchai Development, Ta Ann, Unimech, China Automobile, Scomi Eng, Flonic Hi-Tec, Southern Steel and Hap Seng. Econpile Holdings Bhd has clinched a piling works contract for the East Klang Valley Expressway (EKVE) project package 1 and 2 from Ahmad Zaki Sdn Bhd, valued at RM76.
The FBM KLCI fell 0.73% at mid-morning today in line with the slump at regional markets. At 10am, the FBMKLCI fell 11.76 points to 1,616.79. The top losers…
KUALA LUMPUR (Jan 18): The FBM KLCI fell 0.73% at mid-morning today in line with the slump at regional markets. At 10am, the FBMKLCI fell 11.76 points to 1,616.79. The top losers included Petronas Gas Bhd, Shell Refining Company (Federation of Malaya) Bhd, Latitude Tree Holdings Bhd, Petronas Dagangan Bhd, Malaysia Airports Holdings Bhd, Allianz (M) Bhd, Bintulu Port Holdings Bhd and Malaysian Pacific Airports Bhd.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...